Skip to main content

Melanoma

On October 13, 2023, the FDA approved a new indication for nivolumab (Opdivo; Bristol-Myers Squibb), a PD-1 inhibitor, for the adjuvant treatment of completely resected stage IIB/C melanoma in patients aged ≥12 years. The FDA granted this application an orphan drug designation. Read More ›

During the 2023 American Association for Cancer Research Annual Meeting, experts presented results from a phase 2b clinical trial demonstrating a significant improvement in recurrence-free survival in patients with high-risk melanoma who were treated with a combination of an investigational personalized mRNA-based vaccine plus the immune checkpoint inhibitor pembrolizumab (Keytruda), compared with pembrolizumab alone. Read More ›

The combination of dabrafenib and trametinib performs as well in the real world as in clinical trials in patients with BRAF V600-mutated advanced melanoma and brain metastases, but the medical need for patients with brain metastases remains high. Read More ›

The combination of ipilimumab and anti–PD-1 therapy showed efficacy comparable to clinical trial populations in patients with preexisting autoimmune disease and advanced melanoma. Read More ›

A review of posts to health-related social media over a 5-year period reveals that symptoms and their impact are the most frequently discussed topics by patients with melanoma and their caregivers. Read More ›

In a landmark single-institution analysis of patients with advanced melanoma, those who stopped their immunotherapy within 7 months of achieving a complete response had comparable disease-free survival to those who were treated for longer than 7 months. Read More ›

Real-world analysis suggests that ipilimumab/nivolumab should be considered over a single-agent PD-1 inhibitor for metastatic melanoma, regardless of BRAF status. Read More ›

BRAF/MEK-targeted therapy rechallenge in patients with BRAF-mutation–positive advanced melanoma whose disease progress on first-line BRAF-targeted therapy and second-line immunotherapy leads to responses in approximately one-fourth of patients. Read More ›

The latest analysis of the phase 3 EORTC 1325/KEYNOTE-054 clinical trial showed pembrolizumab to be superior to placebo after more than 3.5 years of follow-up on the end points of distant metastasis-free survival and relapse-free survival in patients with resected stage III melanoma. Read More ›

In an analysis of a French melanoma database, 43% of patients treated with anti–PD-1 therapy experienced a late-onset immune-related adverse event, defined as an event occurring after ≥2 years of treatment. Read More ›

Page 1 of 2